Management Team


The management team is made up of proven industry veterans who have successfully started up and managed biotechnology organizations and companies. The team has a proven track record developing anticancer and infectious disease drugs and also commercializing and taking drugs through the entire development process.

FRANK K. BEDU-ADDO, PH.D. headshot

Frank K. Bedu-Addo, Ph.D.

President and CEO

Dr. Bedu-Addo is a veteran biotech executive with experience successfully starting and growing biotechnology organizations. He has been responsible for the development and implementation of both operational and drug development strategies, supervising and managing both large organizations and emerging biotechnology companies. Dr. Bedu-Addo was a founding and senior executive at KBI BioPharma, Inc. As Vice President of Drug Development, he oversaw all business and drug development operations. Before his tenure at KBI, he successfully started and managed Cardinal Health’s East Coast biotechnology drug development operations. Prior to Cardinal Health, Dr. Bedu-Addo was an Associate Director at Akzo-Nobel, Senior Scientist at Elan (The Liposome Co.), and Principal Scientist at Schering-Plough. In these positions, he contributed to the development of numerous drugs, including antiviral and anticancer products. Dr. Bedu-Addo obtained his M.S. in Chemical Engineering and Ph.D. in Pharmaceutics from the University of Pittsburgh.

  • About Us

    PDS Biotechnology Corporation logo image

    PDS Biotechnology is a clinical stage biopharmaceutical company developing novel cancer immunotherapies and vaccines for infectious diseases.

  • Contact Us

    PDS Biotechnology Corporation
    Commercialization Center for Innovative Technologies (CCIT)

    675 US Highway One
    North Brunswick, NJ 08902

    Tel: 732-640-0145
    Fax: 732-640-0144

GREGORY L. CONN, PH.D. headshot

Gregory L. Conn, Ph.D.

Chief Scientific Officer

B.S., Chemistry, M.S., Ph.D., Biochemistry — Albert Einstein College of Medicine, NY

Dr. Conn has more than 35 years of drug-development expertise, including development of antiviral and anticancer drugs through to commercialization. He is a graduate of the Albert Einstein College of Medicine, where he obtained both his M.S. and Ph.D., discovering novel angiogenic molecules in the human brain. Dr. Conn started his pharmaceutical career at Merck, Sharpe, and Dohme, where he continued his work on novel angiogenic factors, discovering and characterizing the VEGF family of growth factors, work which led to the development and commercialization of the anti-cancer drug Avastin. He was later a leading scientist at Regeneron Pharmaceuticals, where he established and headed various groups in the Cell and Molecular Biology and Drug Discovery departments. Dr. Conn subsequently became a Director in the Process Development department at Covance Biotechnology Services Inc., a contract research and development and drug manufacturing organization, where he supervised the analytical development teams responsible for drug characterization, method development and drug stability studies, and program teams responsible for developing drug manufacturing processes. Dr. Conn has expertise across all phases of the drug development process, including FDA and regulatory requirements, is the co-inventor of eight drug patents, and was a founding member of the PDS team as CSO.


Michael King, M.B.A.

Chief Financial Officer/Chief Business Officer

Mr. King is the former CBO and CFO at Aprecia Pharmaceuticals Company, a specialty pharmaceutical company developing branded specialty products using three-dimensional printing, a unique pharmaceutical manufacturing technology. Mr. King was also previously Chief Commercial Officer of Belrose Pharma, and Head of US Product Portfolio & Strategy and a member of the US Executive Committee for Sandoz GmbH, the $9 billion subsidiary of Novartis AG. A former management consultant with McKinsey & Company, Mr. King has a diverse background in corporate finance and investment banking with deep knowledge of the pharmaceutical/life science industry. Mr. King holds an M.B.A. with Honors from the Columbia Graduate School of Business.

Robert Shepard, M.D. image

Robert C. Shepard, M.D.

Chief Medical Officer

Dr. Shepard is a leading authority on clinical oncology and immunotherapy. He has led the clinical development of multiple notable oncology drugs and immunotherapies over the past 20 years. Most recently, Dr. Shepard served as the global lead for several ongoing cancer trials at AstraZeneca, including prostate and breast cancer trials. Dr. Shepard was previously Chief Medical Officer at Callisto Pharmaceuticals and Cornerstone Pharmaceuticals, where he led the clinical development of cancer drugs. He was also the Medical Director of Oncology Clinical Research & Development at AstraZeneca, and served as a Medical Officer at the FDA’s CBER Division, Oncology Branch, where he was involved in the medical review of the ground-breaking cancer drugs Avastin® and Erbitux®. Dr. Shepard is board-certified in Oncology, Hematology, and Internal Medicine. He is an Attending Physician at Duke University School of Medicine and honorary Professor of Clinical Medicine at The University of North Carolina School of Medicine. He has taught at Harvard, Johns Hopkins, the University of Virginia, and Duke. Dr. Shepard is a member of the American Society of Clinical Oncology, American Society of Hematology, and American Association for Cancer Research, as well as the European Society for Medical Oncology and has published extensively in prominent oncology journals. Dr. Shepard graduated magna cum laude in Biochemical Sciences and Molecular Biophysics from Harvard College, and earned his M.D. degree at Duke University.